Correction: 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis

van der Heijde D, Deodhar A, FitzGerald O, *et al.* 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. *RMD Open* 2018;4:e000582. doi: 10.1136/rmdopen-2017-000582.

Several changes were inadvertently missed during the production stage. These corrections are now incorporated into the current version.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

RMD Open 2018;0:e000582corr1. doi:10.1136/rmdopen-2017-000582corr1